Advertisement
Advertisement

Spotlight Center on HIV Prevention Today

News

Researchers Discuss Questions Surrounding HIV Treatment, Prevention

October 9, 2015

After the HPTN 052 trial settled the question of whether early HIV treatment prevents transmission of the virus, the START trial settled the question of the value of treatment for individual health, Dr. Myron Cohen noted during a talk Thursday.

That leaves two big questions in the wake of the World Health Organization release of updated HIV treatment guidelines, recommending all people infected with HIV receive antiretroviral therapy without delay, he said. One centers on the logistics of delivering antiretroviral therapy to all 37 million people living with the virus, he said, the other on how to reach people during acute HIV infection, which occurs shortly after acquisition of the virus.

Treating people within the first few weeks of infection ensures that immune cell -- or CD4 -- counts remain high and viral load remains low, Cohen said. Treating early after infection not only improves health outcomes for individuals, limiting reservoirs of the virus, but lowers risk of transmission at a critical point. For this reason, Cohen said, public health efforts in his home state of North Carolina are focusing on "cluster busting," or targeting networks of people at high risk for HIV infection, including men who have sex with men, with early antiretroviral therapy.

Advertisement
Some individuals, Cohen said, can even go without antiretrovirals for long periods of time if treated very early.

The question now is, "how much damage are we doing by missing acute infection, a little or a lot," Cohen said.

HIs talk came during a session on HIV prevention, which also featured an update on topical microbicides to protect against acquisition of the virus.

It is a measure that needs an image makeover, said Jeanne Marrazzo of the University of Washington. That makeover, she said, might include a better name than "microbicides."

She noted that clinical trials have shown low adherence and limited marketability and uptake of microbicides combined with the proven impact of treating infected people on preventing transmission have raised questions about the value of microbicides.

This excerpt was cross-posted with the permission of Science Speaks. Read the full article.



This article was provided by Science Speaks. It is a part of the publication IDWeek 2015. Visit Science Speaks' website to find out more about their activities and publications.


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.